Evaluation of the Real-Q BRAF V600E Detection Assay in Fine-Needle Aspiration Samples of Thyroid Nodules Kyung Sun Park, Young L. Oh, Chang-Seok Ki, Jong-Won Kim The Journal of Molecular Diagnostics Volume 17, Issue 4, Pages 431-437 (July 2015) DOI: 10.1016/j.jmoldx.2015.03.006 Copyright © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions
Figure 1 Correlation between cytological diagnosis, two molecular methods for detecting the BRAF V600E mutation, histological diagnosis, and clinical monitoring in the present study. Clinically benign indicates serial ultrasound observations with no interval change or size reduction in the nodule status, repeated fine-needle aspiration (FNA) cytology negative for malignant cells, or no BRAF V600E mutation detected in FNA during clinical monitoring (over 12 months); clinically indeterminate, serial ultrasound observations with interval change or repeated indeterminate FNA cytology; and clinical malignancy, serial ultrasound observations with malignancy or repeated FNA cytology with malignancy, and detection of BRAF V600E mutation, but not determined histologically. AS/PCR, allele-specific PCR; AUS/FLUS, atypia of undermined significance/follicular lesion of undetermined significance; FA, follicular adenoma; FC, follicular carcinoma; FN/SFN, follicular or oncocytic (Hürthle cell) neoplasm/suspicious for follicular or oncocytic (Hürthle cell) neoplasm; ND, not determined; PTC, papillary thyroid carcinoma; Real-Q, Real-Q BRAF V600E detection kit; SMC, suspicious for malignant cells. The Journal of Molecular Diagnostics 2015 17, 431-437DOI: (10.1016/j.jmoldx.2015.03.006) Copyright © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions